Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 976

1.

Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia.

Strous RD, Maayan R, Lapidus R, Stryjer R, Lustig M, Kotler M, Weizman A.

Arch Gen Psychiatry. 2003 Feb;60(2):133-41.

PMID:
12578430
3.

Elevation of the cortisol/dehydroepiandrosterone ratio in schizophrenia patients.

Ritsner M, Maayan R, Gibel A, Strous RD, Modai I, Weizman A.

Eur Neuropsychopharmacol. 2004 Aug;14(4):267-73.

PMID:
15163435
5.

Circulatory neurosteroid levels in smoking and non-smoking chronic schizophrenia patients.

Iancu I, Tchernihovsky E, Maayan R, Poreh A, Dannon P, Kotler M, Weizman A, Strous RD.

Eur Neuropsychopharmacol. 2007 Jul;17(8):541-5. Epub 2007 Mar 8.

PMID:
17346944
6.

Hormonal profile effects following dehydroepiandrosterone (DHEA) administration to schizophrenic patients.

Strous RD, Maayan R, Kotler M, Weizman A.

Clin Neuropharmacol. 2005 Nov-Dec;28(6):265-9.

PMID:
16340380
7.

Depressive and anxiety symptoms in patients with schizophrenia and schizophreniform disorder.

Emsley RA, Oosthuizen PP, Joubert AF, Roberts MC, Stein DJ.

J Clin Psychiatry. 1999 Nov;60(11):747-51.

PMID:
10584762
8.

Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.

Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M.

Arch Gen Psychiatry. 1999 Jan;56(1):29-36.

PMID:
9892253
9.
10.

State and trait related predictors of serum cortisol to DHEA(S) molar ratios and hormone concentrations in schizophrenia patients.

Ritsner M, Gibel A, Maayan R, Ratner Y, Ram E, Modai I, Weizman A.

Eur Neuropsychopharmacol. 2007 Mar;17(4):257-64. Epub 2006 Nov 14.

PMID:
17107774
11.

Dehydroepiandrosterone (DHEA) augmentation in the management of schizophrenia symptomatology.

Strous RD.

Essent Psychopharmacol. 2005;6(3):141-7. Review.

PMID:
15869021
12.

Alterations in DHEA metabolism in schizophrenia: two-month case-control study.

Ritsner M, Gibel A, Ram E, Maayan R, Weizman A.

Eur Neuropsychopharmacol. 2006 Feb;16(2):137-46. Epub 2005 Sep 1.

PMID:
16139994
13.

Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression.

Schmidt PJ, Daly RC, Bloch M, Smith MJ, Danaceau MA, St Clair LS, Murphy JH, Haq N, Rubinow DR.

Arch Gen Psychiatry. 2005 Feb;62(2):154-62.

PMID:
15699292
14.
15.
16.

Improvement of extrapyramidal symptoms following dehydroepiandrosterone (DHEA) administration in antipsychotic treated schizophrenia patients: a randomized, double-blind placebo controlled trial.

Nachshoni T, Ebert T, Abramovitch Y, Assael-Amir M, Kotler M, Maayan R, Weizman A, Strous RD.

Schizophr Res. 2005 Nov 15;79(2-3):251-6. Epub 2005 Aug 26.

PMID:
16126372
17.

Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.

Olié JP, Spina E, Murray S, Yang R.

Int Clin Psychopharmacol. 2006 May;21(3):143-51.

PMID:
16528136
18.

[Negative symptoms, depression, anxiety and alexithymia in DSM III-R schizophrenic patients].

Nkam I, Langlois-Thery S, Dollfus S, Petit M.

Encephale. 1997 Jul-Aug;23(4):267-72. French.

PMID:
9417392
19.

A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety.

Anil Yağcioğlu AE, Kivircik Akdede BB, Turgut TI, Tümüklü M, Yazici MK, Alptekin K, Ertuğrul A, Jayathilake K, Göğüş A, Tunca Z, Meltzer HY.

J Clin Psychiatry. 2005 Jan;66(1):63-72.

PMID:
15669890
20.

Negative correlation between negative symptoms of schizophrenia and testosterone levels.

Goyal RO, Sagar R, Ammini AC, Khurana ML, Alias AG.

Ann N Y Acad Sci. 2004 Dec;1032:291-4.

PMID:
15677432

Supplemental Content

Support Center